Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE


Primary Symbol: ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by Duster340on Jun 29, 2021 3:59pm
229 Views
Post# 33467613

Tax Loss Selling

Tax Loss Sellingcandidate. who would have thunk it only a couple of months ago, remember the recent fire side chats and the virtual investor conferences in early march, well they were telling a different story back then about how close ate was i mean "we are right there dan said'', BP is knocking on the door. partners, buyout, nasdaq. don't feel bad guys even robert mcwhirter got fooled, you could see it on his face and hear it in his comments last time he was asked about ate on BNN. and it was only his next earlier apperance on BNN when he commented on how he talked extensively with ate management and that he participated in the $6 financing.then only a few days later after the financing cannacord dumped shares, obviously cannacord was in the loop, mcwhirter and share holders were not. best way to get even is for share holders to dump there shares before first week of october, make management take a hit on there rsu's. if still interested in ate buy back next year likely at a discount.
glta
<< Previous
Bullboard Posts
Next >>